ReviewClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2022
Pharmacology, particle deposition and drug administration techniques of intranasal corticosteroids for treating allergic rhinitis.
Review in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Administration Technique of Intranasal Corticosteroid Sprays Among Nepali Pharmacists: Cross-Sectional Study.JMIRx med · 2026Article
- Gut microbiome modulation in allergic rhinitis: from current evidence to emerging therapies.Frontiers in allergy · 2026Review
- Impact of nasal and inhaled corticosteroids on SARS-CoV-2 infection susceptibility.The Journal of allergy and clinical immunology · 2025Article
- Azelastine-Fluticasone Combination Therapy in Allergic Rhinitis: Current Evidence and Clinical Implications in Children and Adults.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Comparative analysis of drug deposition patterns among three commercial nasal spray brands: A computational and experimental study.Journal of molecular liquids · 2025Article
- A multidisciplinary Delphi consensus on budesonide aqueous nasal spray in managing upper respiratory diseases.Multidisciplinary respiratory medicine · 2025Article
- Orthonasal and retronasal olfactory function in patients with chronic rhinosinusitis without nasal polyps undergoing endoscopic sinonasal surgery.International forum of allergy & rhinology · 2025Article
- Acoustic therapy for allergic rhinitis and chronic rhinosinusitis: modulating microbiome, immunity and well-being.Frontiers in allergy · 2025Review
- An Overview of Adherence-What It Is and Why It Is Important.The journal of allergy and clinical immunology. In practice · 2024Review
- Inter-societal Delphi Consensus on the topical nasal treatments in Italy.Multidisciplinary respiratory medicine · 2024Article
- Article
- Correlation among post-surgery recurrence of CRSwNP and TCM syndromes and tissue inflammatory cell infiltration type: a study protocol.Systematic reviews · 2024Article
- The Efficacy of Elonide Nasal Corticosteroids in Managing Allergic Rhinitis: A Randomized, Double-Blinded Trial.Journal of clinical medicine · 2024Article
- Pathogenesis of allergic diseases and implications for therapeutic interventions.Signal transduction and targeted therapy · 2023Review
- Pharmacology, particle deposition and drug administration techniques of intranasal corticosteroids for treating allergic rhinitis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review presents an overview of the available literature regarding intranasal corticosteroids (INCs) for the treatment of allergic rhinitis (AR). Various treatment options exist for AR including INCs, antihistamines and leucotriene antagonists. INCs are considered to be the most effective therapy for moderate-to-severe AR, as they are effective against nasal and ocular symptoms and improve quality of life. Their safety has been widely observed. INCs are effective and safe for short-term use. Local adverse events are observed but generally well-tolerated. The occurrence of (serious) systemic adverse events is unlikely but cannot be ruled out. There is a lack of long-term safety data. INC may cause serious eye complications. The risk of INCs on the hypothalamic-pituitary-adrenal axis, on bone mineral density reduction or osteoporosis and on growth in children, should be considered during treatment. Pharmacological characteristics of INCs (e.g. the mode of action and pharmacokinetics) are well known and described. We sought to gain insight into whether specific properties affect the efficacy and safety of INCs, including nasal particle deposition, which the administration technique affects. However, advances are lacking regarding the improved understanding of the effect of particle deposition on efficacy and safety and the effect of the administration technique. This review emphasizes the gaps in knowledge regarding this subject. Advances in research and health care are necessary to improve care for patients with AR.
Indexed as
Identifiers
35947495What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.